There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
ML351 is a novel chemotype and the first reported selective inhibitor of 15-LOX-1 with IC50 value of 200 nM. It is a tight binding, mixed inhibitor which could protect against oxidative glutamate toxicity in mouse neuronal cells (HT-22) and significantly reduced infarct size in an in vivo mouse model for ischemic stroke.
ML351 细胞实验
Cell Line
Concentration
Treated Time
Description
References
mouse islets
10 μmol/L
24 hours
ML351 reduced 12-HETE release and improved glucose-stimulated insulin secretion.
Diabetes. 2017 Nov;66(11):2875-2887
Keratinocytes in human skin equivalents
10 µM
24 or 48 hours
ML351 significantly elevated the secretion of CCL2, CCL5, and CXCL10, indicating its enhancement of keratinocyte inflammatory responses.
Cell Death Dis. 2025 Jan 22;16(1):39
NHEK/SVTERT3-5 cells
10 µM
24 hours
ML351 significantly reduced many metabolites of arachidonic and linoleic acid, indicating its inhibition of lipoxygenase activity.
Cell Death Dis. 2025 Jan 22;16(1):39
Primary spinal microglia
100 ng/ml
8 and 24 hours
To assess the effect of KLA treatment on 15-LOX-1 protein expression. KLA treatment significantly upregulated 15-LOX-1 protein expression in microglia.
Pain. 2018 Dec;159(12):2620-2629
HEK-293T cells
0.1 nM-10 μM
30 minutes
To evaluate the inhibitory effects of ML351 and ML127 on 15-LOX-1 and 12-LOX-p activity. ML351 significantly inhibited the activity of 15-LOX-1 and 12-LOX-p at low nanomolar concentrations, while ML127 preferentially reduced 15-LOX-1 activity.
Pain. 2018 Dec;159(12):2620-2629
human lung macrophages
10 μM
24 hours
To evaluate the inhibitory effect of ML351 on chemokine release induced by LPS and Th2 cytokines. Results showed that ML351 significantly inhibited LPS-induced release of CCL2 and CCL3, as well as IL-4-induced release of CCL13 and CCL22.
Br J Pharmacol. 2015 Sep;172(17):4319-30
ML351 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6J mice
Streptozotocin (STZ)-induced type 1 diabetes model
Intraperitoneal injection
10, 24, 48 mg/kg
Once daily, starting 5 days before STZ and ending 5 days after the last STZ dose
ML351 (10 and 24 mg/kg) prevented diabetes development, reduced β-cell oxidative stress, and preserved β-cell mass. The 48 mg/kg dose was ineffective.
Diabetes. 2017 Nov;66(11):2875-2887
Mice
Subarachnoid hemorrhage model
Intraperitoneal injection
50 mg/kg
Administered 5 minutes after SAH induction, assessed 1 and 3 days later
To evaluate the impact of ML351 on brain injury after SAH. Results showed that ML351 reduced neuronal cell death and improved neurological outcomes.
Stroke. 2019 Feb;50(2):520-523
C57BL6J mice
Transient middle cerebral artery occlusion (MCAO) model
Intraperitoneal injection
50 mg/kg
Single dose
ML351 reduced hemorrhagic transformation (HT) in wild-type mice and similarly reduced HT following tPA treatment
Stroke. 2017 Feb;48(2):445-451
Male Holtzman Sprague-Dawley rats
TLR4-dependent NSAID-unresponsive hyperalgesia model
Intrathecal injection
0.1–10 μg/10 μl
Single injection, 30 minutes pretreatment
To evaluate the inhibitory effects of ML351 and ML127 on TLR4-mediated hyperalgesia. ML351 significantly attenuated hyperalgesia at all tested doses, while ML127 showed dose-dependent inhibition at high doses.
Pain. 2018 Dec;159(12):2620-2629
Mice
LepRdb/db mice (type 2 diabetes model)
Intraperitoneal injection
100mg/kg
7 consecutive days
To evaluate the effect of ML351 on vascular function and diastolic function in diabetic mice, results showed that ML351 improved endothelium-dependent vasodilation and left ventricular diastolic function
Life Sci. 2021 Nov 1;284:119925
Male Swiss Albino mice
Ischemia/recanalization (I/R) model
Intraperitoneal injection
50 mg/kg
Single dose at recanalization
To investigate the effects of ML351 on ischemia/recanalization-induced neuroinflammation. Results showed that ML351 significantly reduced infarct volume, neurological deficit score, and lipid peroxidation, and suppressed inflammasome (NLRP1 and NLRP3) activation.
Front Cell Neurosci. 2023 Sep 26;17:1277268
Mice
Alox12 knockout mice
Intraperitoneal injection
10 mg/kg body weight
5 days prior to STZ treatment, during treatment, and 5 days post-STZ treatment, daily administration
To evaluate the protective effect of ML351 on STZ-induced glucose intolerance, results showed that ML351 treatment significantly improved glucose tolerance in Alox12 knockout mice
搜索
HazMat Fee +
